For the year ending 2025-12-31, BRTX had $963,298 increase in cash & cash equivalents over the period. -$10,905,032 in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -14,241,975 |
| Depreciation and amortization | 209,985 |
| Dividend and interest income | 270,573 |
| Stock-based compensation | 3,325,626 |
| Change in fair value of warrant liabilities | 1,121,502 |
| Accounts receivable | -172,900 |
| Prepaid expenses and other current assets | -101,770 |
| Accounts payable | 839,525 |
| Accrued expenses and other current liabilities | 195,281 |
| Net cash used in operating activities | -10,788,963 |
| Sale of marketable securities | 11,692,686 |
| Purchase of marketable securities | 2,679,147 |
| Purchases of equipment | 116,069 |
| Net cash provided by investing activities | 8,897,470 |
| Proceeds from issuance of common stock for cash | 3,096,250 |
| Payment of issuance costs | 177,953 |
| Exercise of stock options | 41,165 |
| Payment of deferred offering costs | 99,973 |
| Repayment of financed insurance premiums | 4,698 |
| Net cash provided by financing activities | 2,854,791 |
| Net increase (decrease) in cash and cash equivalents | 963,298 |
| Cash and cash equivalents - beginning of the year | 547,890 |
| Cash and cash equivalents - end of the year | 1,511,188 |
BioRestorative Therapies, Inc. (BRTX)
BioRestorative Therapies, Inc. (BRTX)